Amygdala Neurosciences, Inc.   Report issue

For profit Phase 2
Founded: Palo Alto CA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03203499
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Amygdala Neurosciences

Active Ingredients

Drugs in Phase 2 Trials (1)

ans-6637 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1